华海药业：琥珀酸美托洛尔缓释片和盐酸尼卡地平注射液获药品注册证书

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the registration of two new drugs, which are expected to generate significant sales in the domestic market in 2024 [1] Group 1: Product Approvals - The company has obtained the drug registration certificate for Succinic Acid Metoprolol Sustained-Release Tablets, which are used for treating hypertension and angina, with an estimated domestic market sales amount of approximately 3.066 billion yuan in 2024 [1] - The company has also received approval for Nicardipine Hydrochloride Injection, intended for emergency treatment of abnormal hypertension during surgery, with an estimated domestic market sales amount of around 632 million yuan in 2024 [1] Group 2: R&D Investment - The company has invested approximately 17.04 million yuan in the research and development of Succinic Acid Metoprolol Sustained-Release Tablets [1] - The investment in the research and development of Nicardipine Hydrochloride Injection amounts to about 4.98 million yuan [1]